157 related articles for article (PubMed ID: 36907021)
1. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review.
Lai-Kwon J; Inderjeeth AJ; Lisy K; Sandhu S; Rutherford C; Jefford M
Eur J Cancer; 2023 May; 184():83-105. PubMed ID: 36907021
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study.
Thiem A; Mashhadiakbar P; Cussigh C; Hassel JC; Grimmelmann I; Gutzmer R; Schlaak M; Heppt MV; Dücker P; Hüning S; Schulmeyer L; Schilling B; Haferkamp S; Ziemer M; Moritz RKC; Hagelstein V; Terheyden P; Posch C; Gaiser MR; Kropp P; Emmert S; Müller B; Tietze JK
J Eur Acad Dermatol Venereol; 2023 May; 37(5):884-893. PubMed ID: 36433671
[TBL] [Abstract][Full Text] [Related]
6. Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review.
Egeler MD; van Leeuwen M; Fraterman I; van den Heuvel NMJ; Boekhout AH; Lai-Kwon J; Wilthagen EA; Eriksson H; Haanen JB; Wilgenhof S; Ascierto PA; van Akkooi ACJ; van de Poll-Franse LV
Crit Rev Oncol Hematol; 2023 Mar; 183():103919. PubMed ID: 36736511
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors.
Looman EL; Cheng PF; Lai-Kwon J; Morgan L; Wakkee M; Dummer R; Dimitriou F
Cancer Med; 2023 Jun; 12(11):12861-12873. PubMed ID: 37119050
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
9. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
10. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
[TBL] [Abstract][Full Text] [Related]
11. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
12. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
13. Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.
Egeler M; Lai-Kwon J; Tissier R; Fraterman I; Kuijpers A; Van Houdt W; Wilgenhof S; Rao A; Sandhu S; Lee R; Eriksson H; van Leeuwen M; de Ligt K; van Akkooi A; van de Poll-Franse L
Eur J Cancer; 2024 Mar; 200():113601. PubMed ID: 38340383
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
15. From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
Kamminga NCW; van der Veldt AAM; Wakkee M; van den Berge FR; van der Beek LAA; Joosen MCW; Joosse A; de Joode K; Nijsten TEC; Lugtenberg M
BMC Cancer; 2024 May; 24(1):662. PubMed ID: 38816701
[TBL] [Abstract][Full Text] [Related]
16. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
17. Mixed exercise training for adults with fibromyalgia.
Bidonde J; Busch AJ; Schachter CL; Webber SC; Musselman KE; Overend TJ; Góes SM; Dal Bello-Haas V; Boden C
Cochrane Database Syst Rev; 2019 May; 5(5):CD013340. PubMed ID: 31124142
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment.
Aamdal E; Skovlund E; Jacobsen KD; Straume O; Kersten C; Herlofsen O; Karlsen J; Hussain I; Amundsen A; Dalhaug A; Nyakas M; Hagene KT; Holmsen K; Aamdal S; Kaasa S; Guren TK; Kyte JA
ESMO Open; 2022 Oct; 7(5):100588. PubMed ID: 36116420
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.
Mulder EEAP; Smit L; Grünhagen DJ; Verhoef C; Sleijfer S; van der Veldt AAM; Uyl-de Groot CA
ESMO Open; 2021 Dec; 6(6):100303. PubMed ID: 34781194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]